BioCheetah Pte Ltd’s cover photo
BioCheetah Pte Ltd

BioCheetah Pte Ltd

Biotechnology Research

SINGAPORE, Singapore 537 followers

We use proprietary biomarkers to develop non-invasive immunodiagnostic kits for the diagnosis of urological cancers.

About us

BioCheetah is a Singapore-based, Agency Science Technology and Research(A*STAR)-Institute of Molecular and Cell Biology(IMCB) spin-off company. It is primarily set up to develop and commercialize non-invasive, protein-based immunodiagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by BioCheetah’s Scientific Founder (Prof. Jean-Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee). Products to be developed include professional use in-vitro diagnostic ELISA and Point-of-care test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. There are several clinical trials for clinical validation of the bladder cancer diagnostic products is currently underway locally and with several hospitals worldwide.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
SINGAPORE, Singapore
Type
Privately Held
Founded
2018
Specialties
in-vitro diagnostics, rapid test, bladder cancer, urological cancers, POCT, Point-of-care test, and ELISA

Locations

  • Primary

    79 Ayer Rajah Crescent

    #05-09

    SINGAPORE, Singapore 139955, SG

    Get directions

Employees at BioCheetah Pte Ltd

Updates

Similar pages